Aims/hypothesis Anti-zinc transporter (ZnT)8 autoantibodies are commonly detected in type 1 diabetic patients. We hypothesised that ZnT8 is also recognised by CD8 + T cells and aimed to identify HLA-A2 (A*02:01)-restricted epitope targets. Methods Candidate epitopes were selected by ZnT8 plasmid DNA immunisation of HLA-A2/DQ8 transgenic mice and tested for T cell recognition in peripheral blood mononuclear cells of type 1 diabetic, type 2 diabetic and healthy participants by IFN-γ enzyme-linked immunospot. Results White HLA-A2 + adults (83%) and children (60%) with type 1 diabetes displayed ZnT8-reactive CD8 + T cells that recognised a single ZnT8 [186][187][188][189][190][191][192][193][194] (VAANIVLTV) epitope. This ZnT8 186-194 -reactive fraction accounted for 50% to 53% of total ZnT8-specific CD8 + T cells. Another sequence, ZnT8 153-161 (VVTGVLVYL), was recognised in
20% and 25% of type 1 diabetic adults and children, respectively. Both epitopes were type 1 diabetes-specific, being marginally recognised by type 2 diabetic and healthy participants (7-12% for ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] , 0% for ZnT8 [153] [154] [155] [156] [157] [158] [159] [160] [161] 
Introduction
The autoimmune cascade leading to beta cell destruction in type 1 diabetes is propagated by T cell recognition of specific epitopes. Epitope mapping is therefore critical for staging of autoimmunity during the disease, and for developing and monitoring immunomodulatory therapies. Indeed, a combination of multiple epitope markers is likely to track beta cell autoimmunity more efficiently than any single epitope. Likewise, restoring immune tolerance to a broad antigen spectrum may be clinically more effective [1] . Zinc transporter (ZnT)8 was recently identified as a major type 1 diabetes antigen, with 60-80% of recent-onset type 1 diabetic participants harbouring antibodies against its Cterminal domain [2] . As for other beta cell antigens, such autoantibodies are likely to be accompanied by autoreactive T cells targeting ZnT8 [1] . Indeed, ZnT8-reactive CD4 + and CD8 + T cells were recently described in white and Chinese type 1 diabetic patients, respectively [3, 4] . Given their central role in beta cell autoimmunity [5, 6] , further characterisation of these CD8 + T cells is needed. Here, we identify a highly immunodominant ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] epitope recognised by such cells.
Methods

ZnT8 peptide library
We synthesised 70 nonamer peptides (>75% purity; ProImmune, Oxford, UK) that had been selected as potential binders to HLA-A1, -A2, -A3, -A24, -B7 and -B8 (electronic supplementary material [ESM] Table 1 ). Binding to recombinant HLA-A2 molecules was assessed using Class I REVEAL assays (ProImmune). Candidate epitopes were re-synthesised at >90% purity.
DNA immunisation HLA-A2/DQ8 transgenic (A*02:01/ DQB1*03:02) H-2D
mice were obtained by crossing HLA-A2 and HLA-DQ8 transgenic mice [7, 8] . These mice were pretreated with cardiotoxin and vaccinated twice with non-coding plasmid or plasmid encoding full-length human ZnT8 (1:1 mixture of Arg/Trp 325 isoforms) cloned into pcDNA3.1, as described previously [7] . The study was approved by the local ethics committee. Splenocytes were plated (5×10 5 /well) in IFN-γ enzyme-linked immunospot (ELISpot) plates (Millipore, Molsheim, France) along with peptides (10 μmol/l). After culturing for 20 to 24 h, plates were treated with a biotinylated anti-IFN-γ antibody (U-CyTech, Utrecht, the Netherlands), alkaline phosphatase-conjugated streptavidin and NBT-BCIP (Sigma, Lyon, France). Triplicate wells were counted and averaged using a Bioreader 5000 Pro-SF equipment (BioSys, Karben, Germany). ). Serum antibodies were measured by RIA, using 35 S-labelled GAD65, the intracellular part of protein tyrosine phosphatase-2 (IA-2ic) and ZnT8 (construct C-term CRCW JH6.2). All participants were HLA-A2 + (HLA-A*02:01) by genotyping and gave written informed consent. Local ethics committees approved the study.
Study participants
ELISpot assays Peripheral blood mononuclear cells (PBMCs) prepared as described previously [5] were used fresh or frozen-and-thawed with similar results [5, 9] . PBMCs (3×10 5 /well) were seeded in anti-IFN-γ-coated ELISpot plates in AIM-V medium (Life Technologies, Saint Aubin, France) containing 0.5 ng/ml IL-7 and 10 μmol/l peptide. A viral peptide mix (Flu MP 58-66 , Epstein-Barr virus BMLF 280-288 , cytomegalovirus pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] ) and phytohaemagglutinin (1 μg/ml) were used as positive controls. Pyruvate dehydrogenase (PD) [5] [6] [7] [8] [9] [10] [11] [12] [13] and DMSO diluent were negative controls. After 20 to 24 h, plates were developed and counted as above. For blocking experiments, anti-CD8 (OKT8, 25 μg/ml) or anti-HLA-A2 (BB7.2, 50 μg/ml, both in-house) were added to wells. Readouts are expressed as spot-forming cells (SFC)/10 6 PBMCs after subtracting background responses against PD [5] [6] [7] [8] [9] [10] [11] [12] [13] and no peptide (which were identical in all cases). The positive cut-off was set at 3 SD above the average background, as determined by receiveroperator characteristics analysis [5] . Intra-and inter-assay CVs are 14% and 9%, respectively [5] .
Statistics Values are expressed as mean± SD or median (range), according to distribution. Comparisons between proportions were made with Fisher's exact test.
Results
We used DNA immunisation [7] to pinpoint naturally processed and presented HLA-A2-restricted epitopes derived from ZnT8 (Fig. 1a) . Based on positive responses (i.e. >3 SD above background) in >15% (≥2/12) of immunised mice, ten candidates were selected (Fig. 1b, ESM Table 1 ). None was positive in control immunised mice. Similar results were obtained using HLA-A2 transgenic mice lacking the DQ8 transgene [7] (data not shown). Most candidate epitopes were located in the fourth transmembrane region (3/10) or in the C-terminal domain (3/10). None overlapped with the Arg/Trp 325 polymorphic region.
Binding assays to recombinant HLA-A2 molecules were performed in parallel (Fig. 1c) . While most (8/10; 80%) candidate epitopes identified by DNA immunisation were strong HLA-A2 binders, two epitopes (number 50, ZnT8 253-261 and number 57, ZnT8 280-288 ) were weak binders. In addition, several epitopes (22/30; 73%) that were strong HLA-A2 binders did not elicit significant responses in DNA-immunised mice. Thus, compared with epitope selection based on HLA-binding affinity, DNA immunisation allowed us to focus on fewer candidates (10/70 vs 30/70; 14% vs 43%), including two weakly binding peptides. Moreover, DNA immunisation selects candidates on the additional criterion of natural processing and presentation [7] .
The identified peptides were subsequently tested for CD8 + T cell recognition using PBMCs from type 1 diabetic, type 2 diabetic and healthy participants. Results are summarised in Fig. 2a and raw ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] was targeted in 73% of type 1 diabetic patients, without significant differences between adults (83%) and children (60%). PBMCs from type 2 diabetic patients and healthy controls rarely recognised this epitope (12% and 7%, respectively; p≤0.009 for both compared with type 1 diabetic adults or children), while ZnT8 253-261 (number 50; FIFSILVLA) was more frequently recognised in type 2 (25%) than in type 1 diabetic (8% adults, 10% children) and healthy participants (0%; p 00.007 for comparison between type 2 diabetic and healthy). ZnT8 153-161 and ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] were strong HLA-A2 binders, were located in transmembrane regions and positive in 75% and 58% of immunised mice, respectively. IFN-γ ELISpot assays Fig. 2 Recognition of HLA-A2-restricted ZnT8 epitopes in different study participants. a Per cent of new-onset type 1 diabetic adults (blue bars; n012) and children (red bars; n010), and of type 2 diabetic (grey bars; n024) and healthy participants (white bars; n027) responding to each individual epitope by IFN-γ ELISpot. b IFN-γ ELISpot responses were measured in a type 1 diabetic adult using PBMCs stimulated in the presence of no antibody (Ab), isotype control antibody, anti-CD8 or anti-HLA-A2 antibody. Counts (mean±SD) of triplicate wells are given without background subtraction for each of the indicated peptide stimuli, i.e. no peptide (white bars), ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] (light grey bars) and ZnT8 253-261 (dark grey bars). c Patient A03 was tested at four subsequent time-points for PBMC reactivities against the peptides ZnT8 186-194 (circles) and ZnT8 153-161 (diamonds), and the viral mix (squares). Results are expressed as mean IFN-γ SFC/10 6 PBMCs and are background-subtracted. d Relative distribution of epitope specificities in type 1 diabetic (T1D) adults and children as indicated. The per cent prevalence of each epitope out of all epitopes recognised among new-onset type 1 diabetic adults (n019) and children (n012) is shown (n014) were performed using two different ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] peptide batches and yielded identical results in 13 (93%) of 14 assays. Moreover, reactivity to ZnT8 epitopes was neutralised by anti-CD8 and anti-HLA-A2 antibodies (Fig. 2b) , demonstrating that IFN-γ responses originated from CD8 + T cells that recognised HLA-A2-restricted epitopes. As previously observed for GAD-and IA-2-reactive CD8 + T cells [5, 7] and for ZnT8-reactive CD4 + T cells [3] , there was no correlation between anti-ZnT8 T cell and autoantibody responses (data not shown).
The median frequency of ZnT8 epitope-reactive CD8 + T cells in new-onset type 1 diabetic patients (34.5 SFC/10 6 PBMCs, i.e. 0.003%, range 0.0007-0.08%) was similar to that previously observed for other beta cell epitopes [5, 7] . Moreover, one type 1 diabetic adult patient (identified as A03) was studied at four different time points (Fig. 2c) . While IFN-γ responses to a viral mix remained fairly stable over time, frequencies of ZnT8 186-194 -reactive T cells secreting IFN-γ gradually increased over time, while the corresponding ZnT8 153-161 -reactive T cells rapidly disappeared.
The immunodominance of ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] was also evident when considering its relative representation among all epitopes recognised (Fig. 2d) . Indeed, ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] was the most frequently targeted peptide in type 1 diabetic adults and children (53% and 50% of total ZnT8-reactive CD8 + T cell responses, respectively) compared with other epitopes.
Discussion
ZnT8 is clearly a major target of autoreactive CD8 + T cells in white new-onset type 1 diabetic patients. Strikingly, a single HLA-A2-restricted ZnT8 186-194 epitope was recognised by the overwhelming majority of ZnT8-reactive T cells (50-53%), and in both type 1 diabetic adults (83%) and children (60%). Another epitope, ZnT8 153-161 , ranked second, being recognised in 20% to 25% of type 1 diabetic patients. Such a high degree of epitope focusing is surprising, as autoreactivity is usually more widely distributed against different sequences [5] . Indeed, the two most immunodominant epitopes described to date are GAD 114-123 [5] and preproinsulin (PPI) 15-24 [6] , which are recognised iñ 50% of type 1 diabetic adults compared with the 83% scored by ZnT8 [186] [187] [188] [189] [190] [191] [192] [193] [194] . An increase in ZnT8 186-194 -reactive IFN-γ responses during the disease was also observed in one patient, contrary to observations for most epitope reactivities, including ZnT8 153-161 , which rapidly wane after diagnosis [9] . ZnT8 253-261 was recognised in 25% of type 2 diabetic patients, a population seldom included in previous T cell studies. The phenotype of these patients was not distinctive; they were all antibody-negative and all but one not being treated with insulin. However, it is possible that larger ad hoc studies focusing on patients of uncertain classification may reveal a discrete subset.
The epitopes here identified do not overlap with those targeted by CD4 + T cells [3] . The subdominant ZnT8 153-161 epitope was also recognised by PBMCs of Chinese HLA-A2 + recent-onset type 1 diabetic patients [4] . In contrast, the novel ZnT8 186-194 emerges here as the major epitope recognised. Intriguingly, we recently described the same ZnT8 186-194 epitope and its contiguous ZnT8 178-186 sequence as targets of autoantibody responses in~60% of Sardinian type 1 diabetic patients [10] . These autoantibodies were cross-reactive with homologous sequences of the Mycobacterium avium paratuberculosis (MAP) 3865c protein, prompting the hypothesis that MAP could be an environmental trigger of type 1 diabetes via a molecular mimicry mechanism [10] . It would therefore be relevant to investigate whether ZnT8 186-194 -reactive CD8 + T cells also cross-recognise MAP3865c 133-141 , which, if confirmed, could explain their high prevalence.
